Literature DB >> 30706421

L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic.

Roger F Butterworth1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30706421     DOI： 10.1007/s40265-018-1021-4

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  6 in total

Review 1.  Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles.

Authors:  Karin Weissenborn
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

2.  L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.

Authors:  Ali Canbay; Jan-Peter Sowa
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 3.  Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.

Authors:  Gerald Kircheis; Stefan Lüth
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 4.  L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.

Authors:  Roger F Butterworth; Mark J W McPhail
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 5.  Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues.

Authors:  Sara Montagnese; Jasmohan S Bajaj
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 6.  Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology.

Authors:  Roger F Butterworth
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.